Abivax jumps as fully exercised option lifts share-sale haul to $920 million
Abivax said underwriters fully exercised an option to buy additional ADSs, raising gross proceeds from a recent offering to $920 million (7.36M ADSs), versus $800 million initially. Net proceeds were $874.1 million. The company plans to use funds for potential U.S. commercialization of obefazimod and ongoing trials; it expects funding through Q2 2029. Shares rose in premarket.
How this was made
The 30-second read
Why it matters
Fully exercised underwriter options increased the offering size and proceeds, improving funding visibility through Q2 2029 and lowering time pressure often associated with takeover talks.
Market read
Traders can reassess Abivax’s near-term liquidity risk and financing-driven sentiment ahead of the July 6 offering close.
What to watch
The article notes potential M&A remains possible, but provides no new bid/terms; the market may overreact to optionality until concrete deal signals emerge.
Background
Abivax is a French biotech developing obefazimod for chronic inflammatory conditions and is in late-stage Phase 3 trials.
Ticker impact
Abivax said underwriters fully exercised an option to buy additional ADSs, lifting gross proceeds to $920M and boosting premarket shares 6.7%.
Near-term upside bias likely persists while traders price in improved funding runway; magnitude may fade after the July 6 delivery/closing.
The article discloses a new, time-sensitive capital raise expansion (additional ADSs, higher proceeds) and ties it to a specific use of funds and runway through Q2 2029.
Market effects
Biotech financing conditions may look supportive as follow-on ADS exercises can extend cash runway without immediate dilution pressure beyond the announced raise.
Paris-listed peers may see mild sentiment spillover given the same company’s ADR-linked move.
Limited broader impact; primarily affects Abivax’s capital structure and perceived acquisition optionality.
Counterpoint
The expanded raise can also signal the company still needs substantial capital to reach commercialization, which may cap upside if investors focus on dilution rather than runway.
Key entities
- companyAbivax
Nasdaq-listed French biotechnology company; expanded ADS offering to $920M gross proceeds.
- drug_candidateobefazimod
Lead drug candidate in late-stage Phase 3 trials; commercialization and clinical research funded by proceeds.
